Affymetrix launches platform for next-generation genotyping
20 October 2009
Affymetrix, Inc. (Nasdaq:AFFX) has launched the Axiom
Genotyping Solution, its next-generation array technology designed to
match the significant rise in genetic content generated by government
and privately funded sequencing projects.
This high-throughput, automated platform enables researchers to find
novel genetic variations associated with complex disease.
The Axiom Solution will support both whole-genome association and
candidate gene association studies with a level of customization not
currently available. Researchers will no longer be constrained by the
content of fixed-panel arrays. The complete genotyping platform employs
enzyme-mediated, single-base sequencing steps for specificity in
conjunction with affordable, reproducible, and highly automated
The solution is configured to continually validate and incorporate
the output of large-scale sequencing projects. Initial offerings are
designed from public databases of human variations and cover historical
HapMap data supplemented by subsequent releases of additional variants.
In addition, Affymetrix is screening millions of putative SNPs and
insertions/deletions that are being discovered by the 1000 Genomes
Project and other sources, and will make these available to researchers
using the Axiom Solution.
“Axiom technology has the capability to routinely screen, validate,
and convert sequence variants into high-throughput assays,” said Dr.
Keith Jones, vice president of assay and application development at
Affymetrix. “A major strength of this new solution is the assay that
allows random access to the genome, coupled with the accuracy of a
highly specific, ligation-based approach.”
The solution consists of Axiom Array Plates, complete Axiom Reagent
Kits, and an automated target preparation station developed jointly by
Affymetrix and Beckman Coulter, and the GeneTitan Multi-Channel (MC)
Instrument. The GeneTitan MC Instrument integrates a hybridization oven,
fluidics processing, CCD imaging device, and analysis software for
maximum data reproducibility, user productivity, and scalability.
With a single platform and as few as one-and-a-half full-time
technicians, a laboratory can process more than 750 samples per week
with unmatched, minimal user intervention. The first commercial products
from this offering will support genome-wide association studies and are
expected to be delivered to customers this month.
“The Axiom Solution is a revolution in customer choice and takes
advantage of a technology model similar to the digital media industry,”
said Kevin King, president and CEO of Affymetrix. “Pre-selected,
store-bought music and video content have given way to powerful online
digital databases that offer customers maximum flexibility. Researchers
can now create their own 'playlist' in the form of custom arrays that
deliver maximum scientific value to their research.”
Affymetrix will also offer Axiom Genotyping Services through the
Affymetrix Research Services Laboratory (ARSL), which has run more than
250,000 genotyping samples to date, including a large portion of the
Wellcome Trust Case Control Consortium.